News | March 24, 2025
AstraZeneca to invest $2.5 billion in new global strategic R&D centre in China
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
The company has also launched its first three 24*7 pharmacy stores via COCO model in Bengaluru
The new office in New Delhi marks a significant funding in the APAC region and reinforces the company’s commitment to advancing respiratory care in India
Talicia is also approved and launched in the UAE and additional countries may accept UK MHRA approvals as a reference for their own marketing approval processes
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Empamore is poised to make a significant impact by offering high-quality treatment at an affordable price point, empowering millions of Indians to take control of their health
Experts urge early detection & better access to care
Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant
Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M
The MDR certification reafirms that these products meet the highest safety, quality, and regulatory standards
Subscribe To Our Newsletter & Stay Updated
